AnHeart
在场
AnHeart 的所有者是 Nuvation Bio.
是其中之一......
Nuvation Bio 是一家在股票代码 NUVB (US) 下上市的公司。
涉及Nuvation Bio的并购和融资。
- Nuvation Bio has announced the acquisition of AnHeart (公布2024四月12号).
高管
查看带有其 16 名主要高管的组织结构图
AnHeart 搜索最多的简介
高管在AnHeart变化
- Amy Muse已作为Vice President, US Commercial加入公司 (新闻发布的2023十一月10号).
- Guilin Huang已作为Senior Vice President, Development加入公司 (新闻发布的2023十一月10号).
- Charlotte Arnold已作为Chief Corporate Affairs Officer加入公司 (新闻发布的2023九月29号).
高管在Nuvation Bio变化
- Colleen Sjogren已作为Chief Commercial Officer加入公司 (新闻发布的2024三月29号).
- Robert Mashal已作为Director加入公司 (新闻发布的2024一月9号).
- Jennifer Fox, Chief Financial Officer, 已经离开公司 (新闻发布的2023十一月14号).
创建提醒
跟踪 AnHeart 的高管变动
生物技术
Nuvation Bio 拥有 2,284 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Transcarent 刚刚宣布为 126 筹款数百万美元。 (公布2024五月2号).
- WindRose Health Investors has announced the acquisition of SubjectWell (公布2024五月2号).
- Enlaza Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024五月2号).
生物技术 行业的其他推荐联系人
消息
AnHeart 的最新新闻稿
- Nuvation Bio Completes Acquisition of AnHeart Therapeutics
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
- AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
- AnHeart Therapeutics and Innovent Announce China’s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
- AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 Inhibitor
- AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)
- AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads
- AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan
- AnHeart Therapeutics’ Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial
- AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer
- View more press releases Close
通过电子邮件
